MedKoo Cat#: 564898 | Name: 3,4-Dephostatin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

3,4-Dephostatin is an inhibitor of the interactions of CFTR-associated ligand (CAL) and PSD-95/Dlg1/ZO-1 (PDZ) domain.

Chemical Structure

3,4-Dephostatin
3,4-Dephostatin
CAS#173043-84-0

Theoretical Analysis

MedKoo Cat#: 564898

Name: 3,4-Dephostatin

CAS#: 173043-84-0

Chemical Formula: C7H8N2O3

Exact Mass: 168.0535

Molecular Weight: 168.15

Elemental Analysis: C, 50.00; H, 4.80; N, 16.66; O, 28.54

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MN30; MD; Methyl-3,4-dephostatin; 3,4-Dephostatin; 3,4 Dephostatin
IUPAC/Chemical Name
N-(3,4-Dihydroxyphenyl)-N-methylnitrous amide
InChi Key
XAKAQCMEMMZUEO-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H8N2O3/c1-9(8-12)5-2-3-6(10)7(11)4-5/h2-4,10-11H,1H3
SMILES Code
O=NN(C1=CC=C(O)C(O)=C1)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 168.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhao Y, Cushing PR, Smithson DC, Pellegrini M, Pletnev AA, Al-Ayyoubi S, Grassetti AV, Gerber SA, Guy RK, Madden DR. Cysteine modifiers suggest an allosteric inhibitory site on the CAL PDZ domain. Biosci Rep. 2018 Jul 6;38(4). pii: BSR20180231. doi: 10.1042/BSR20180231. Print 2018 Aug 31. Erratum in: Biosci Rep. 2018 Jun 5;:. PubMed PMID: 29472314. 2: Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2010 Feb 19;2(1):5. doi: 10.1186/2040-2384-2-5. PubMed PMID: 20298531; PubMed Central PMCID: PMC2831839.